Focus: Siga is a public biotechnology company focused on small-molecule antivirals for infectious diseases, with a market-leading position in orthopoxvirus treatment through its flagship product TPOXX (tecovirimat). The company generates meaningful revenue from government stockpiling and commercial demand for mpox and smallpox countermeasures.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Siga to get notified when they start hiring — the background below is worth knowing for when they do.
Sole approved antiviral for orthopoxviruses with dual LOE dates (2031–2032); drives >80% of company revenue through government contracts and commercial demand.
Help build intelligence for Siga
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Siga's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results - The Manila Times
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results The Manila Times
A Look At SIGA Technologies (SIGA) Valuation After Its Latest Special Dividend Announcement - simplywall.st
A Look At SIGA Technologies (SIGA) Valuation After Its Latest Special Dividend Announcement simplywall.st
Siga Technologies (NASDAQ:SIGA) Options Surge Hits Nasdaq 100 Index - Kalkine Media
Siga Technologies (NASDAQ:SIGA) Options Surge Hits Nasdaq 100 Index Kalkine Media
A Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract Progress - Yahoo Finance
A Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract Progress Yahoo Finance
8-K Filing: SIGA TECHNOLOGIES INC (SIGA) (CIK 0001010086) — EXHIBIT 99.1
EXHIBIT 99.1
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Segmental validation of the 50-kHz phase angle as a valid, practical proxy that closely approximates the characteristic-frequency phase angle and associations with muscle function and body water: A cross-sectional study.
Coexistence of domains composed of intercellular lipids in stratum corneum as studied by X-ray diffraction and differential scanning calorimetry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo